Resumen

CRUZ, Joana  y  COSTA, Ana Rosa. Levonorgestrel-releasing intrauterine system and breast cancer. Acta Obstet Ginecol Port [online]. 2017, vol.11, n.4, pp.276-282. ISSN 1646-5830.

Levonorgestrel intrauterine system (LNG-IUS) is a highly effective long-term contraception that causes endometrial suppression with considerably lower systemic exposure than oral progesterone. It is currently approved for the treatment of abnormal uterine bleeding, dysmenorrhea, for endometrial protection during estrogen therapy and its use in patients with breast cancer taking tamoxifen (TMX) is being debated. The aim of this systematic review was to describe the risk of breast cancer in LNG-IUS users and to define it safety in women taking adjuvant TMX following breast cancer, for the outcomes of endometrial and uterine pathology and secondary breast cancer events

Palabras clave : Intrauterine device; Medicated intrauterine device; levonorgestrel-releasing intrauterine system; Breast neoplasm; Breast cancer.

        · texto en Portugués     · Portugués ( pdf )